171 related articles for article (PubMed ID: 35500016)
1. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers.
Hollmén M; Maksimow M; Rannikko JH; Karvonen MK; Vainio M; Jalkanen S; Jalkanen M; Mandelin J
Mol Cancer Ther; 2022 Jul; 21(7):1207-1218. PubMed ID: 35500016
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of
Moisio O; Virta J; Yatkin E; Liljenbäck H; Palani S; Viitanen R; Miner MWG; Oikonen V; Tolvanen T; Vugts DJ; Taimen P; Li XG; Hollmén M; Jalkanen S; Roivainen A
J Nucl Med; 2023 Apr; 64(4):555-560. PubMed ID: 36302655
[TBL] [Abstract][Full Text] [Related]
3. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH; Verlingue L; de Miguel M; Pasanen A; Robbrecht D; Skytta T; Iivanainen S; Shetty S; Ma YT; Graham DM; Arora SP; Jaakkola P; Yap C; Xiang Y; Mandelin J; Karvonen MK; Jalkanen J; Karaman S; Koivunen JP; Minchom A; Hollmén M; Bono P
Cell Rep Med; 2023 Dec; 4(12):101307. PubMed ID: 38056464
[TBL] [Abstract][Full Text] [Related]
4. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Virtakoivu R; Rannikko JH; Viitala M; Vaura F; Takeda A; Lönnberg T; Koivunen J; Jaakkola P; Pasanen A; Shetty S; de Jonge MJA; Robbrecht D; Ma YT; Skyttä T; Minchom A; Jalkanen S; Karvonen MK; Mandelin J; Bono P; Hollmén M
Clin Cancer Res; 2021 Aug; 27(15):4205-4220. PubMed ID: 34078651
[TBL] [Abstract][Full Text] [Related]
5. Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments.
Rannikko JH; Bono P; Hynninen J; Hollmén M
Cancer Immunol Res; 2024 Jan; 12(1):48-59. PubMed ID: 37922365
[TBL] [Abstract][Full Text] [Related]
6. Clever-1/stabilin-1 controls cancer growth and metastasis.
Karikoski M; Marttila-Ichihara F; Elima K; Rantakari P; Hollmén M; Kelkka T; Gerke H; Huovinen V; Irjala H; Holmdahl R; Salmi M; Jalkanen S
Clin Cancer Res; 2014 Dec; 20(24):6452-64. PubMed ID: 25320356
[TBL] [Abstract][Full Text] [Related]
7. Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages.
Palani S; Maksimow M; Miiluniemi M; Auvinen K; Jalkanen S; Salmi M
Eur J Immunol; 2011 Jul; 41(7):2052-63. PubMed ID: 21480214
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Antibody Production in Clever-1/Stabilin-1-Deficient Mice.
Dunkel J; Viitala M; Karikoski M; Rantakari P; Virtakoivu R; Elima K; Hollmén M; Jalkanen S; Salmi M
Front Immunol; 2018; 9():2257. PubMed ID: 30349531
[TBL] [Abstract][Full Text] [Related]
9. New tools to prevent cancer growth and spread: a 'Clever' approach.
Hollmén M; Figueiredo CR; Jalkanen S
Br J Cancer; 2020 Aug; 123(4):501-509. PubMed ID: 32595212
[TBL] [Abstract][Full Text] [Related]
10. Lymphatic expression of CLEVER-1 in breast cancer and its relationship with lymph node metastasis.
Ammar A; Mohammed RA; Salmi M; Pepper M; Paish EC; Ellis IO; Martin SG
Anal Cell Pathol (Amst); 2011; 34(1-2):67-78. PubMed ID: 21483103
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8
Viitala M; Virtakoivu R; Tadayon S; Rannikko J; Jalkanen S; Hollmén M
Clin Cancer Res; 2019 Jun; 25(11):3289-3303. PubMed ID: 30755440
[TBL] [Abstract][Full Text] [Related]
12. Clever-1 positive macrophages in breast cancer.
Mutka M; Virtakoivu R; Joensuu K; Hollmén M; Heikkilä P
Breast Cancer Res Treat; 2022 Oct; 195(3):237-248. PubMed ID: 35917053
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
14. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
[TBL] [Abstract][Full Text] [Related]
15. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
16. Stage I-IV Colorectal Cancer Prognosis Can Be Predicted by Type and Number of Intratumoral Macrophages and CLEVER-1
Ålgars A; Kemppinen L; Fair-Mäkelä R; Mustonen H; Haglund C; Jalkanen S
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885098
[TBL] [Abstract][Full Text] [Related]
17. Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages.
Fraser DA; Tenner AJ
J Immunol; 2010 Oct; 185(7):3932-9. PubMed ID: 20833838
[TBL] [Abstract][Full Text] [Related]
18. Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium.
Irjala H; Alanen K; Grénman R; Heikkilä P; Joensuu H; Jalkanen S
Cancer Res; 2003 Aug; 63(15):4671-6. PubMed ID: 12907648
[TBL] [Abstract][Full Text] [Related]
19. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
20. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties.
Zhang J; Huang Y; Xi G; Zhang F
MAbs; 2020; 12(1):1724751. PubMed ID: 32106752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
